CRTC2 and lymphoid neoplasm: To overcome this potential mechanism of resistance, dual TORC1/TORC2 inhibitors26, 27 were evaluated and found to be more cytotoxic than rapamycin in primary samples of a variety of lymphoid neoplasms exposed ex vivo.28, 29